From the analyst's couch: Next-generation antibodies.
Visiongain, BSG HOUSE, 230 City Road, London, EC1V 2QY, UK.
James B
JB
Evans
IMS Health, 210 Pentonville Road, London N1 9JY, UK.
Basharut A
BA
Syed
D000906:Antibodies / Q000737:chemistry / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000737:chemistry / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016527:Drug Costs; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics; D015202:Protein Engineering
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D000922:Immunotoxins; D008024:Ligands